Wedbush Downgrades Artiva Biotherapeutics to Neutral, Lowers Price Target to $4

Benzinga · 6d ago
Wedbush analyst David Nierengarten downgrades Artiva Biotherapeutics (NASDAQ:ARTV) from Outperform to Neutral and lowers the price target from $40 to $4.